| Effect of somatostatin versus octreotide on portal haemodynamics in patients with cirrhosis and portal hypertension. | |
| | |
MedLine Citation:
|
PMID: 15647641 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Elevated portal inflow is part of the pathogenesis of portal hypertension in patients with cirrhosis. Vasoactive substances appear to play a primary role in the regulation of portal flow. The aim of this study was to investigate the effects of somatostatin and octreotide on portal pressure and plasma levels of insulin-like growth factor (IGF-1), nitric oxide (NO), endothelin-1 (ET-1) and glucagon (GLU). METHODS: Portal pressures of 14 cirrhotic patients with portal hypertension who underwent transjugular intrahepatic portosystemic shunt (TIPS) were directly measured via a catheter placed in the portal vein. Portal pressure and IGF-1, NO, ET-1 and GLU plasma levels were determined at baseline, and at 8 h and 24 h after administration of somatostatin or octreotide via portal vein catheter in a randomized, double-blind, cross-over design. RESULTS: The average decrease in portal pressure after intravenous infusion of somatostatin and octreotide was 9.4 +/- 1.0 cmH2O and 5.0 +/- 1.0 cmH2O, respectively (P < 0.01). Plasma levels of GLU and IGF-1 decreased significantly 8 and 24 h after somatostatin and octreotide infusion (P < 0.05). However, there were no significant decreases in plasma NO or ET-1 levels. There was a significant difference between somatostatin and octreotide groups (P < 0.01). CONCLUSION: Both somatostatin and octreotide can significantly reduce portal pressure, although somatostatin is more potent than octreotide. The underlying mechanisms may involve inhibition of the secretion of GLU, IGF-1 and other hormones as well as a decrease in hepatic metabolism and portal inflow leading to a reduction in portal pressure. |
| | |
Authors:
|
Jian-Fen Yang; Xing-Jiang Wu; Jie-Shou Li; Jien-Min Cao; Jian-Ming Han |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: European journal of gastroenterology & hepatology Volume: 17 ISSN: 0954-691X ISO Abbreviation: Eur J Gastroenterol Hepatol Publication Date: 2005 Jan |
Date Detail:
|
Created Date: 2005-01-13 Completed Date: 2005-04-12 Revised Date: 2009-10-16 |
Medline Journal Info:
|
Nlm Unique ID: 9000874 Medline TA: Eur J Gastroenterol Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 53-7 Citation Subset: IM |
Affiliation:
|
Research Institute of General Surgery, Jinling Hospital Nanjing 210002, Jiangsu Province, China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cross-Over Studies Double-Blind Method Female Glucagon / blood Humans Hypertension, Portal / blood, drug therapy*, etiology, physiopathology Insulin-Like Growth Factor I / metabolism Liver Cirrhosis / blood, complications*, physiopathology Male Middle Aged Octreotide / therapeutic use* Portal Pressure / drug effects Somatostatin / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
51110-01-1/Somatostatin; 67763-96-6/Insulin-Like Growth Factor I; 83150-76-9/Octreotide; 9007-92-5/Glucagon |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intracellular cytokine expression in peritoneal monocyte/macrophages obtained from patients with cir...
Next Document: The administration of N-acetylcysteine causes a decrease in prothrombin time in patients with parace...